Streetwise Reports' Article Archives — November 2021 back to current month (25)
ImmunoGen Inc. shares traded 30% higher after the company announced positive topline data from its pivotal Phase 3 SORAYA Trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer.
Oramed Pharmaceuticals' oral vaccine offers "convenience and safety advantages as well as coverage of emergent variant strains," noted a Nov. 29, 2021 H.C. Wainwright & Co. report.
Just a few days after the WHO deemed the COVID-19 Omicron variant a serious global health concern, leading mRNA-based vaccine developers BioNTech and Pfizer, along with rival Moderna, advised that if needed, the companies would be capable of developing a vaccine for the new mutating strains within roughly 100 days. H.C. Wainwright & Co. commented in a research note that it reiterates its "Buy" rating for BioNTech SE.
Shares of NRx Pharmaceuticals Inc. traded 50% higher after the company commented on new data released by the Israel Institute for Biological Research regarding the effectiveness of its BriLife® COVID-19 Vaccine against the SARS-CoV-2 "Delta" variant.
Shares of Krystal Biotech Inc. reached a new 52-week high after the company reported it met both primary and secondary endpoints in its pivotal GEM-3 trial of VYJUVEK™ in patients diagnosed with Dystrophic Epidermolysis Bullosa, a rare and severe skin disease.
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome.
Shares of Dicerna Pharmaceuticals Inc. traded 78% higher after the company reported it entered into a definitive agreement to be acquired by Novo Nordisk A/S of Denmark for $38.25 per share in cash.
Shares of Novavax Inc. traded 10% higher after the firm confirmed that the European Medicines Agency is now reviewing its COVID-19 vaccine filing for conditional marketing authorization. The firm advised that an opinion from the agency is expected within a few weeks.
Shares of Kezar Life Sciences Inc. rose to a new 52-week high after the company reported promising interim results from its Phase 2 trial of KZR-616 in patients with lupus nephritis.
Shares of EyePoint Pharmaceuticals Inc. reached a new 52-week intraday high after the company reported positive data from its Phase 1 DAVIO study of EYP-1901 in Wet AMD and announced plans to move forward to additional Phase 2 clinical trials in 2022.
"We believe this data begins to form the basis of an approvable program for Compass Pathways' COMP360" in this indication, noted a BTIG report.
Contakt World plans to build a diversified health technology SaaS platform and address inequity of health access through technology.
Invitae Corp. reported Q3/21 financial results that highlighted an 89% YoY increase in billable volume to 296,000 tests. Ladenburg Thalmann & Co. Inc. stated in a research note that it has a "Buy" rating for the company with a $55.00/share price target.
Stereotaxis Inc. shares traded higher after the company reported Q3/21 financial results and confirmed its FY/21 revenue guidance. The company added that it is sufficiently funded and is on pace towards doubling its system revenue in FY/22.
Shares of Seres Therapeutics Inc. traded 20% higher after the company reported Q3/21 financial results and announced it is partnering with Bacthera in Switzerland to manufacture medicine for use in c.Diff treatment.
Clinics that deliver novel psychiatric treatment and host clinical trials of psychedelic medicine have positioned Novamind for breakthroughs in mental health treatment.
Results expected are for trials of Jounce Therapeutics' two lead product candidates, vopratelimab and pimivalimab, both monoclonal antibodies, noted a ROTH Capital Partners report.
Autolus Therapeutics Plc. shares traded 28% higher after the company reported that Blackstone Life Sciences is investing up to $250 million in the firm to develop obe-cel in treatment of adult Acute Lymphoblastic Leukemia and advance its broader targeted T- Cell technology platform.
Shares of brand, generic and injectable drug maker Endo International traded 25% higher after the company reported Q3/21 financial results and raised its FY/21 revenue and EPS guidance.
Shares of robotic performance-guided surgery device maker Asensus Surgical Inc. traded 21% higher after the company reported Q3/21 financial results that included a 215% increase in YoY revenue.
Surgery Partners shares traded 18% higher after the company reported Q3/21 financial results that included a 12.7% increase in YoY revenue and a 6.2% increase in the number of same-facility procedures performed.
Wedbush Securities Inc. advised that global precision therapy company Blueprint Medicines Corp.'s therapeutic AYVAKIT is gaining traction in patients diagnosed with advanced systemic mastocytosis and gastrointestinal stromal tumors. Wedbush reiterated its Outperform rating for the company and raised its 12-month price target by $4.00 to $136.00 per share.
McAlinden Research Partners estimates it may be only a matter of time before psychedelics become part of a biotech boom.
BTIG commented in a research report that Sigilon Therapeutics is developing a powerful and widely applicable "cell replacement in a bottle" as a potential functional cure for genetic diseases. BTIG advised it is initiating coverage on the company with a "Buy" rating and $14/share price target.
Shares of ANI Pharmaceuticals Inc. traded 50% higher after the company reported the U.S. FDA approved its Purified Cortrophin Gel for use in treating multiple sclerosis, rheumatoid arthritis and nephrotic syndrome.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|